Halozyme Therapeutics, Inc. (NASDAQ:HALO) Shares Sold by Charles Schwab Investment Management Inc.

Charles Schwab Investment Management Inc. cut its holdings in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO) by 0.8% in the 3rd quarter, Holdings Channel reports. The fund owned 1,773,397 shares of the biopharmaceutical company’s stock after selling 14,151 shares during the period. Charles Schwab Investment Management Inc.’s holdings in Halozyme Therapeutics were worth $101,509,000 as of its most recent SEC filing.

Other large investors also recently modified their holdings of the company. Boston Trust Walden Corp bought a new position in shares of Halozyme Therapeutics during the second quarter worth about $23,211,000. Swedbank AB bought a new position in shares of Halozyme Therapeutics during the first quarter worth about $13,927,000. Creative Planning lifted its position in shares of Halozyme Therapeutics by 43.2% during the second quarter. Creative Planning now owns 37,291 shares of the biopharmaceutical company’s stock worth $1,953,000 after purchasing an additional 11,249 shares during the last quarter. Boston Partners lifted its position in shares of Halozyme Therapeutics by 14.1% during the first quarter. Boston Partners now owns 630,368 shares of the biopharmaceutical company’s stock worth $25,500,000 after purchasing an additional 77,976 shares during the last quarter. Finally, Handelsbanken Fonder AB lifted its position in shares of Halozyme Therapeutics by 76.9% during the third quarter. Handelsbanken Fonder AB now owns 1,969,169 shares of the biopharmaceutical company’s stock worth $112,715,000 after purchasing an additional 856,200 shares during the last quarter. 97.79% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity

In related news, SVP Michael J. Labarre sold 10,000 shares of the firm’s stock in a transaction that occurred on Wednesday, September 18th. The shares were sold at an average price of $62.03, for a total transaction of $620,300.00. Following the transaction, the senior vice president now owns 173,756 shares in the company, valued at $10,778,084.68. This trade represents a 5.44 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Over the last 90 days, insiders have sold 60,000 shares of company stock valued at $3,425,000. Insiders own 2.40% of the company’s stock.

Halozyme Therapeutics Stock Performance

HALO opened at $47.79 on Wednesday. The business’s 50 day moving average is $54.28 and its 200-day moving average is $53.68. The stock has a market cap of $6.08 billion, a PE ratio of 15.81, a price-to-earnings-growth ratio of 0.45 and a beta of 1.29. The company has a current ratio of 10.36, a quick ratio of 9.15 and a debt-to-equity ratio of 3.32. Halozyme Therapeutics, Inc. has a twelve month low of $33.15 and a twelve month high of $65.53.

Analysts Set New Price Targets

Several brokerages have recently commented on HALO. Piper Sandler increased their price target on shares of Halozyme Therapeutics from $51.00 to $52.00 and gave the stock a “neutral” rating in a research report on Monday, November 4th. JMP Securities raised their target price on shares of Halozyme Therapeutics from $72.00 to $73.00 and gave the stock a “market outperform” rating in a report on Friday, November 1st. Benchmark reissued a “buy” rating and issued a $60.00 target price on shares of Halozyme Therapeutics in a report on Thursday, August 8th. Cowen reissued a “buy” rating on shares of Halozyme Therapeutics in a report on Friday, October 18th. Finally, Morgan Stanley raised their target price on shares of Halozyme Therapeutics from $59.00 to $64.00 and gave the stock an “overweight” rating in a report on Wednesday, August 7th. Four analysts have rated the stock with a hold rating and seven have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, Halozyme Therapeutics has a consensus rating of “Moderate Buy” and a consensus target price of $61.11.

Halozyme Therapeutics Profile

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.